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Activation of the immune coagulation system has been implicated in the pathogenesis of fulminant liver
failure caused by murine hepatitis virus strain 3 (MHV-3). The recent discovery of the fgl2 gene, which encodes
for MHV-3-induced prothrombinase (fgl2 prothrombinase), allows for fundamental studies to determine the
molecular basis for fulminant liver failure. Transcription of the fgl2 gene and translation of the protein it
encodes were examined in the liver and other organs of susceptible mice following MHV-3 infection. No
constitutive expression of the fgl2 gene or the fgl2 prothrombinase was detected. Within 12 to 24 h of MHV-3
infection, however, fgl2 gene transcripts were detected in large amounts in the liver, spleen, and lungs, all of
which are rich in reticuloendothelial cells, but were only focally present in small amounts in the kidney and
brain. There was sequential detection of fgl2 prothrombinase in the liver, where it was localized specifically to
the endothelium of intrahepatic veins and hepatic sinusoids; this was allowed by fibrin deposition, which
resulted in confluent hepatocellular necrosis. These results provide further evidence for the role of the selective
expression of this novel fgl2 prothrombinase in the pathogenesis of MHV-3-induced fulminant liver failure.
Fibrin deposition is fundamental to pathogenesis in a num-
ber of animal models of liver injury, including that from carbon
tetrachloride, endotoxin, galactosamine, acetaminophen (para-
cetamol), and murine hepatitis virus strain 3 (MHV-3) (23). In
the hepatocellular necrosis associated with these pathological
processes, resident macrophages within the liver (Kupffer
cells) exhibit morphological features of activation and release
inflammatory mediators, including procoagulants, tumor ne-
crosis factor alpha (TNF-a), interleukin-1 (IL-1), proteolytic
enzymes, and eicosanoids as well as superoxide anions and
nitric oxide (12).
Studies from this laboratory have demonstrated a pivotal
role for a procoagulant with prothrombin-cleaving activity
(prothrombinase) in MHV-3-induced hepatic necrosis. Macro-
phages isolated from susceptible (BALB/c) but not from resis-
tant (A/J) animals express large amounts of this prothrombi-
nase in vitro and in vivo. Of great interest is that systemic
inhibition of the prothrombinase with high-titer neutralizing
monoclonal antibody prevents hepatic necrosis and prolongs
survival in MHV-3-susceptible mice (15). These observations
define a unique interface between immune-mediated coagula-
tion and the acute inflammatory disease fulminant hepatitis.
Recently, this laboratory reported the isolation and functional
expression of complementary DNA clones for this prothrom-
binase, termed fgl2 (20). The molecular clone corresponded to
a mouse fibrinogen-like protein (7, 10). Examination of the
predicted protein structure showed 36% sequence similarity
with the C-terminal portion of the beta and gamma subunits of
fibrinogen, similar to other members of the fibrinogen family
of proteins (10). When the entire coding region was expressed
by a coupled vaccinia virus-bacteriophage system in RAW
264.7 cells, a marked expression of prothrombinase activity was
observed (20). Therefore, the gene fgl2 encoded a specific
prothrombinase involved in the pathogenesis of MHV-3 infec-
tion. The murine gene for the fgl2 prothrombinase was local-
ized to proximal regions of mouse chromosome 5 (20, 25). We
and others have shown that MHV-3 replicates in many tissues,
including lung, bowel, brain, kidney, and spleen, in addition to
the liver, and yet disease as defined by fibrin deposition and
cellular necrosis is confined to the liver (11, 16). The present
study demonstrates that following MHV-3 infection of suscep-
tible BALB/c mice, fgl2 mRNA transcripts are strongly induced
in macrophage-rich organs, such as the liver, spleen, and lungs;
however, immunoreactive fgl2 (fgl2 prothrombinase) was ex-
pressed only in the liver. Furthermore, both fgl2 mRNA tran-
scripts and fgl2 prothrombinase were expressed only by Kupffer
cells and endothelial cells and not by hepatocytes of the liver
after MHV-3 infection. The expression of the fgl2 prothrom-
binase was promptly followed by fibrin deposition and massive
hepatic necrosis, hallmarks of fulminant liver disease.
MATERIALS AND METHODS
Mice. Female BALB/c mice, 8 weeks of age, were purchased from Jackson
Laboratory (Bar Harbor, Maine), and were housed in the animal facility at the
Toronto Hospital Research Institute, University of Toronto. Mice were kept in
a controlled-temperature (22°C) environment with 12-h light-dark cycles and
were given access to standard chow (LabDiet; PMI Feeds, Inc., St. Louis, Mo.)
and water ad libitum prior to and during the experiment. Animals acclimatized
to laboratory conditions for 1 week prior to experiments and were handled
strictly according to Guide to the Care and Use of Experimental Animals of the
Canadian Council on Animal Care.
* Corresponding author. Mailing address: Toronto General Hospi-
tal, 621 University Ave., NU-10-151, Toronto, Ontario, Canada






























Reagents. The reagents used in the experiments included RPMI 1640, guani-
dine isothiocyanate, guanidine hydrochloride, redistilled formamide, ethidium
bromide, and Hanks’ balanced salt solution (HBSS) (GIBCO BRL, Life Tech-
nologies, Grand Island, N.Y.); DNA grade agarose (Bio-Rad, Laboratories,
Hercules, Calif.); sodium dodecyl sulfate (SDS) (ICN Biomedicals, Inc., Aurora,
Ohio); formaldehyde solution (Mallinckrodt Specialty Chemicals Company,
Paris, Ky.); salmon sperm DNA, diethylpyrocarbonate (DEPC), and metriz-
amide (Sigma Chemical Co., St. Louis, Mo.); thioglycolate (Difco Laboratories,
Detroit, Mich.); collagenase B and DNase I (Boehringer Mannheim, Quebec,
Canada); pronase (Calbiochem, La Jolla, Calif.); fetal calf serum (FCS) (Flow
Laboratories, Mississauga, Ontario, Canada); and [a-32P]dCTP (3,000 Ci/mmol)
(Amersham, Oakville, Ontario, Canada).
Virus. MHV-3 was plaque purified on monolayers of DBT cells and was grown
to a titer of 1.5 3 107 PFU per ml in 17 CL1 cells. Viral titers were determined
on monolayers of L2 cells by a standard plaque assay as described elsewhere (11,
16).
Organ collection. The livers, spleens, lungs, kidneys, and brains were removed
from BALB/c mice at 2, 4, 6, 8, 16, 24, 36, and 48 h following intraperitoneal
administration of MHV-3 (105 PFU/mouse); organs removed immediately after
MHV-3 injection (0 h) were used as normal controls. The organs were embedded
in a cryoprotectant (O.C.T compound; Miles Inc., Elkhart, Ind.) in cryomolds
and snap frozen in liquid nitrogen. The organs removed 24 h after MHV-3
infection were fixed in 4% paraformaldehyde at room temperature. The fixed
tissue blocks were then embedded in paraffin and sectioned. The frozen organs
were kept in a 280°C freezer until RNA extraction, viral titration, or cryosection
for immunohistochemical staining.
Histological examination of organs after MHV-3 infection. Histological sec-
tions of the liver, spleen, lungs, kidneys, and brain were prepared. The tissues
were cut into 1-by 0.2-cm blocks and were fixed with 10% formalin in 0.1 M
phosphate balanced solution (PBS) (pH 7.4) at the beginning of the experiment
and 24, 36, and 48 h following MHV-3 infection. The tissues were dehydrated in
graded alcohol solutions and xylene and embedded in paraffin, and 4-mm sections
were cut and stained with hematoxylin and eosin (1).
Titration of virus in the organs. Samples of liver, spleen, lungs, kidneys, and
brain were obtained 24 h after MHV-3 infection. Approximately 100 mg of each
frozen (270°C) organ was homogenized in RPMI 1640 supplemented with 2%
FCS and 4 mM glutamine as a 10% homogenate at 4°C, and viral titers were then
determined on L2 cell monolayers by a standard plaque assay as described
previously (11, 16).
Peritoneal macrophages. Peritoneal macrophages from BALB/c mice were
harvested 4 days after intraperitoneal injection of 1.5 ml of 3% thioglycolate as
described previously (13). Macrophages were resuspended at a concentration of
106/ml in RPMI 1640 containing 2 mM glutamine. Macrophages represented a
homogeneous population greater than 95% in purity as determined by morphol-
ogy, nonspecific esterase staining, and staining with Mac-1 antibody (4).
Extraction of total RNA from macrophages. Peritoneal macrophages were
infected with MHV-3 (multiplicity of infection 5 5) and washed free of virus, and
total RNA was extracted as described previously (5) with minor modifications.
Briefly, macrophages were lysed in 8 M guanidine hydrochloride and sheared
with a 25-gauge needle. The lysate was centrifuged at 14,000 rpm and 4°C for 30
min (Eppendorf centrifuge 5402; Netheler-Hinz GmbH, Hamburg, Germany).
The supernatant was mixed with half the volume of 100% ethanol and allowed
to precipitate at 220°C for 40 min, followed by centrifugation at 14,000 rpm at
4°C for 30 min. The pellet was redissolved in 8 M guanidine hydrochloride and
then mixed with half the volume of 100% ethanol for an additional 40 min at
220°C. Total RNA was pelleted by centrifugation at 14,000 rpm at 4°C for 30
min. The RNA pellet was then washed with 70% ethanol repeatedly, vacuum
dried, and resuspended in DEPC-treated water. Total cellular RNA from
MHV-3 infected BALB/c macrophages was used as a positive control for fgl2
mRNA transcript expression.
Isolation of murine nonparenchymal and parenchymal cells of the liver. To
identify which cell populations in the liver (nonparenchymal or parenchymal
cells) expressed fgl2 mRNA transcripts after MHV-3 infection, nonparenchymal
and parenchymal cells were isolated from normal liver or from the liver 24 h after
intraperitoneal administration of MHV-3 (105 PFU/mouse). This method has
been described previously (9, 27). Briefly, mice were anesthetized by intraperi-
toneal injection of sodium pentobartibal (5 mg/100 g of body weight) (Somnotol;
MTC Pharmaceuticals, Cambridge, Ontario, Canada). The abdomen was opened
by midline incision, and the portal vein was exposed and cannulated with silastic
tubing (outer diameter, 0.037 in.; inner diameter, 0.020 in.) (Dow Corning,
Midland, Mich.). The liver was perfused with oxygenated (95% O2 and 5% CO2)
calcium- and magnesium-free HBSS at flow rate of 10 ml/min with a peristaltic
pump (Dig-Staltic; Cole-Parmer Instrument Co., Barrington, Ill.) at 37°C for 10
min. The perfusate was changed to HBSS with calcium, magnesium, 0.02%
collagenase B, and 0.001% DNase I for a further 10 min. The liver was then
removed and placed in a sterile petri dish containing cold (4°C) HBSS with 10%
FCS, in which the liver capsule and attached cells were removed. The cellular
suspension was then centrifuged at 50 3 g at 4°C for 2 min twice after being
passed through a sterile steel cell sieve (60 mesh; Sigma Chemical Co.), and the
supernatant was transferred to a siliconized bottle containing 0.5 mM CaCl2,
followed by incubation with 0.02% pronase and 0.01% DNase I at 37°C for 60
min. The cellular pellets were resuspended in 10 ml of HBSS after centrifugation
at 400 3 g at 4°C for 7 min, and 5 ml of the cell suspension was mixed with 7 ml
of 30% metrizamide, followed by centrifugation at 1,620 3 g at 4°C for 15 min.
The nonparenchymal cell band was collected and washed free of metrizamide
with HBSS, and the cell pellet was snap frozen with liquid nitrogen and stored at
280°C until total RNA extraction.
Extraction of total RNA from tissue. The method of extraction of total RNA
from tissue has been described elsewhere (26). In brief, 100 mg of tissue was
homogenized in a denaturing solution containing 4 M guanidine isothiocyanate,
25 mM sodium citrate, 0.1 M 2-mercaptoethanol, and 0.5% N-lauroylsarcosine.
The homogenate was then mixed with 2 M sodium acetate (pH 4.0), water-
saturated phenol, and chloroform-isoamyl alcohol (49:1) and incubated on ice
for 15 min. The mixture was centrifuged at 15,800 3 g at 4°C for 20 min. The
upper aqueous phase was transferred to a fresh tube and then mixed with an
equal volume of 100% isopropanol and precipitated at 220°C for 30 min. RNA
was pelleted by centrifugation at 15,800 3 g at 4°C for 30 min and then dissolved
in the denaturing solution, to which an equal volume of 100% isopropanol was
added for reprecipitation of RNA at 220°C. After centrifugation, the RNA
pellet was washed with 75% ethanol twice, dried in vacuum, and resuspended in
DEPC-treated water.
Northern blot analysis. Both macrophage (15 mg) and tissue (80 mg) total
cellular RNAs were electrophoresed in a 1% denaturing agarose gel with 1.7%
formaldehyde and then transferred to nitrocellulose membranes (Schleicher &
Schuell, Keene, N.H.) in 20 3 SSC (13 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate). RNA was immobilized by baking the membrane at 80°C for 2 h in
vacuum and was hybridized in 50% formamide–53 SSPE (13 SSPE is 0.18 M
NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7])–53 Denhardt’s solution–
0.5% SDS–100 mg of denatured salmon sperm DNA per ml at 42°C for 18 h with
a [a-32P]dCTP-labeled 1.2-kb DNA probe of murine fgl2 cDNA (7 3 108 cpm/
mg) encompassing nucleotides 861 (ATGGGTGGA . . .) to 2084 (. . . CT-
TACTG) as reported by Parr et al. (20). Labeled human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA was used to ensure equal loading of
RNA. The membrane was washed with 13 SSPE and 0.1% SDS at room tem-
perature for 15 min and then autoradiographed by exposure to Kodak film
(X-OMAT; Eastman Kodak Company, Rochester, N.Y.).
In situ hybridization. The method used here has been described previously
(31). Digoxigenin-11-UTP (Dig-UTP) (Boehringer Mannheim, Quebec, Cana-
da)-labeled cRNA probes (antisense and sense) were synthesized with T7 and T3
RNA polymerases following subcloning of a 650-bp fragment of fgl2 cDNA,
representing nucleotides 846 (TGTGACA . . .) to 1495 (. . . ATGAATC) (20),
into the EcoRI site of pBluescript (Stratagene, La Jolla, Calif.). The Dig-UTP-
labeled probe concentration was determined by immunoenzymatic reaction with
chemiluminescent detection, and the probes were stored at 280°C. Tissue sec-
tions were deparaffinized in 100% xylene and 100% alcohol, followed by prehy-
bridization in 50% formamide and 23 SSC at room temperature for 1 h. The
hybridization mixture consisted of 50% deionized formamide, 5% dextran sul-
fate, 250 mg of salmon sperm DNA per ml, and 2 mg of Dig-labeled cRNA probe
per ml in 23 SSC. The hybridization mixture with the probe was denatured by
heating in an 85°C water bath for 5 min, chilled on ice for 1 min, and added to
tissue sections for hybridization at 42°C overnight. Posthybridization washing in
a series of dilutions of SSC was followed by application of 3% blocking reagent
at room temperature for 30 min. After a brief wash in Tris-HCl buffer (pH 7.5),
sections were incubated with polyclonal anti-Dig Fab fragments, conjugated to
alkaline phosphatase (Boehringer Manheim), diluted 1:500 in Tris-HCl buffer.
Unbound antibody was removed by two 5-min washes with Tris-HCl buffer. A
purple reaction product developed when alkaline phosphatase substrates, 5-
bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitroblue tetrazolium (NBT),
were applied to sections at room temperature for 120 min. Sections were coun-
terstained with methylene green and mounted in Permount for viewing.
Immunohistochemical staining. (i) Immunofluoresence for detection of the
fgl2 prothrombinase. In order to determine whether fgl2 prothrombinase immu-
noreactivity was expressed in the organs where fgl2 mRNA transcripts were
evident following MHV-3 infection, immunohistochemical staining of various
organs was performed with a rabbit polyclonal antibody made against the fgl2
prothrombinase. Snap-frozen tissue specimens were cryosectioned at 6-mm thick-
ness and mounted on glass slides. Tissue slices were fixed with 100% methanol
at 4°C for 5 min and air dried. They were rehydrated with 0.1 M PBS (pH 7.4)
and blocked with 10% normal horse serum in PBS at room temperature for 2 h.
An affinity-purified polyclonal antibody to the murine fgl2 prothrombinase was
produced in rabbits by repeated injections with a 14-amino-acid hydrophilic
peptide (CKLQADDHRDPGGN) from exon 1 of the fgl2 prothrombinase which
had been coupled to keyhole limpet hemocyanin. Tissue slices were first incu-
bated with antibody (30 mg/ml in PBS) at room temperature for 2 h and then
incubated with fluorescein isothiocyanate-conjugated goat immunoglobulin G
(IgG) (6.7 mg/ml) fraction to rabbit IgG Fc (Cappel Laboratories, Durham, N.C.)
at room temperature for 1 h, following which they were washed five times in PBS
with 0.05% Tween 20. Tissue slices were then air dried, mounted with 90%
glycerol, and photographed with a Leitz Laborlux fluorescence S microscope
(Ernst Leitz Wetzlar GmbH, Wetzlar, Germany).
(ii) Immunoperoxidase staining of fibrin. Liver tissue from BALB/c mice
obtained at 0, 24, 36, and 48 h after MHV-3 infection was examined for the
presence of fibrin. The primary antibody used was a rabbit anti-human fibrino-
gen, a purified immunoglobulin fraction of rabbit antiserum (DAKO, Carpinte-










ria, Calif.). The antibody is known to react with native human fibrinogen as well
as with the fibrinogens of other species and with fibrin in human tissues and in
the mouse. The technique utilized for detection of fibrin was the standard
avidin-biotin complex method. The biotinylated secondary antibody was anti-
rabbit IgG linked to peroxidase reacted with 3,39-diaminobenzidine chromagen,
followed by counterstaining with hematoxylin. Serial sections were stained with
hematoxylin and eosin.
Statistical analysis. Quantitative data were expressed as means 6 standard
deviations. Statistical analysis was carried out by using one-way analysis of vari-
ance, and a P value of less than 0.05 was considered statistically significant.
RESULTS
Histology. Tissues, including liver, spleen, lungs, kidneys,
and brain, from mice after MHV-3 infection were examined as
described above. Histopathological changes were found only in
the liver and not in the other organs examined. At 24 h postin-
fection, numerous small, discrete nonzonal foci of necrosis
with a sparse polymorphonuclear leukocyte infiltrate could be
seen in livers from BALB/c mice. At 48 h, these lesions became
larger, more numerous, and frequently panlobular, and there
was early confluent necrosis (Fig. 1). Fibrin deposition was
present but was difficult to recognize (see Fig. 7).
Viral titers in the organs after MHV-3 infection. High titers
of virus were found in all tissues examined. The viral titers in
the liver detected 24 h following MHV-3 infection were signif-
icantly higher than those in the lungs, kidneys, and brain (P ,
0.001), but there was no difference in viral titers between liver
and spleen (P . 0.05) (Fig. 2).
Effect of MHV-3 on steady-state fgl2 mRNA transcripts in
murine tissues. Northern blot analysis of total cellular RNAs
extracted from uninfected and infected organs at various time
points after intraperitoneal administration of MHV-3 is shown
in Fig. 3. The mRNA for fgl2 was not constitutively expressed
in the tissues examined in this study. In the liver, fgl2 mRNA
transcripts were detected at 8 h and persisted to 48 h, the last
time point studied, after MHV-3 injection (Fig. 3A). Similarly,
mRNA transcripts for fgl2 were first detected at 6 h in the
spleen (Fig. 3B) and lungs (Fig. 3C) and persisted for 48 h after
MHV-3 infection. In these organs the mRNA transcripts were
localized to macrophages and endothelial cells. Despite the
presence of mRNA transcripts in the spleen, no fgl2 prothrom-
binase (protein) was detected even at day 5, just prior to death
of the animals. After 48 h, transcripts (mRNA) were not seen
in these tissues. By Northern blot analysis, no constitutive or
FIG. 1. BALB/c mouse liver at 48 h after MHV-3 infection. Confluent hepatocellular necrosis of liver parenchyma is shown (p). Necrotic cells show nuclear
karyorrhexis, loss of cell membranes, and granular disintegration of cell cytoplasm. Fibrin is present as thin strands in the sinusoids (arrowheads). The nonnecrotic
hepatocytes appear histologically normal. Hematoxylin-and-eosin stain was used. Magnification, 3300.
FIG. 2. Determination of viral titers in organs at 24 h following MHV-3
infection. The viral titer in the liver was significantly higher than those in the
lung, kidney, and brain (P , 0.001) but did not differ significantly from that in the
spleen (P . 0.05). Error bars indicate standard deviations.










MHV-3-induced mRNA transcripts of fgl2 were seen in the
kidney or brain at all time points studied (Fig. 3D and E).
fgl2 mRNA expression in cellular subpopulations of the
liver. In order to determine which cell subpopulations of the
liver expressed fgl2 transcripts after MHV-3 infection, paren-
chymal cells (hepatocytes) and nonparenchymal cells (Kupffer
and endothelial cells) were isolated from liver. Total cellular
RNAs extracted from both hepatocytes and nonparenchymal
cells were analyzed by Northern blot analysis, which revealed
that fgl2 gene transcripts were expressed only in nonparenchy-
mal cells (Fig. 4).
In situ hybridization. Liver tissue from uninfected BALB/c
mice hybridized with an antisense or sense probe did not reveal
constitutive fgl2 mRNA expression (data not shown). In con-
trast, within 24 h of MHV-3 infection, fgl2 mRNA transcripts
were evident in endothelial cells and Kupffer cells in MHV-3-
infected BALB/c mice (Fig. 5). fgl2 mRNA expression was seen
in splenic reticuloendothelial cells and macrophages and was
also detected in bronchiolar cells, alveolar duct epithelial cells,
and alveolar macrophages (data not shown). Low-level expres-
sion of fgl2 was seen in the kidney and the brain following
MHV-3 infection (data not shown). In the brain, fgl2 tran-
scripts were found in subcortical neurons, and in the kidney,
the fgl2 transcripts were confined to the tubular epithelium of
the inner medulla.
Immunohistochemical staining. Immunohistochemical stain-
ing of the liver for fgl2 prothrombinase showed that it was not
evident in normal controls (Fig. 6A) but was present only in the
liver following MHV-3 infection, where it was first localized at
24 h postinfection to the sinusoids and large veins (Fig. 6B),
but by 48 h it was seen in sinusoids and large confluent areas
of hepatocellular necrosis (Fig. 6C). fgl2 prothrombinase in-
creased until day 5, when the animals died. fgl2 immunoreac-
tivity was not detected in any other organs, including the
spleen, lungs, kidneys, and brain, either constitutively or fol-
lowing MHV-3 infection (data not shown).
Sections of livers from BALB/c mice examined at the onset
of the experiments showed normal histology, and all were
negative for fibrin. At 24 h after infection, the livers of BALB/c
mice showed fibrin deposits in hepatic sinusoids; the deposits
were randomly distributed as discrete microfoci throughout
the liver. Occasionally, branches of intrahepatic veins also
showed fibrin deposits. Hepatocytes appeared to be completely
normal, except in widely scattered focal areas where liver cell
necrosis was seen. In all instances, the necrosis was confined to
areas where the fibrin deposits were most extensive and in-
volved contiguous sinusoids. The necrotic hepatocytes showed
complete karyorrhexis of nuclei, loss of cell membranes, and
granular disintegration of cell structure, but hepatocytes else-
where were normal. At 36 h these changes had progressed, and
the focal fibrin deposits and focal necrosis pattern had changed
to confluent areas of bridging necrosis and panlobular necrosis.
By 48 h, widespread multifocal areas of fibrin deposition and
hepatocellular necrosis were evident, involving approximately
50% of the liver parenchyma. In every instance, the necrosis
was associated with extensive fibrin deposits. No hepatocellu-
lar necrosis was seen in areas without fibrin deposition. The
parenchyma in nonnecrotic areas still looked normal histolog-
ically. These studies showed a clear-cut progression of his-
topathological changes, beginning with discrete deposits of fi-
brin in sinusoids and progressing to larger areas of fibrin
deposition accompanied by discrete foci of hepatocellular ne-
crosis and finally to areas of confluent hepatic necrosis. In the
larger areas of necrosis, fibrin was present throughout the
lesions, and in some of them, neutrophils were present as well
(Fig. 1 and 7).
FIG. 3. Expression of fg12 mRNA transcripts in tissue after MHV-3 infec-
tion. Eighty micrograms of total RNA was loaded in each well and hybridized
with an fg12 cDNA. Lane 1, RNAs (15 mg) from MHV-3-infected peritoneal
macrophages (positive control); lane 2, RNAs, from organs immediately after
MHV-3 infection (negative control); lanes 3 to 10: RNAs extracted 2, 4, 6, 8, 16,
24, 36, and 48 h, respectively after MHV-3 infection. MHV-3-induced fg12
mRNA transcription in the liver (A) started at 8 h and persisted to 48 h, whereas
expression of fg12 mRNA transcripts was first detected at 6 h in the spleen (B)
and lung (C) and persisted for 48 h. In contrast, fg12 mRNA transcripts were not
detected in the kidney (D) and brain (E) after MHV-3 infection. A GAPDH
cDNA was used to ensure equal levels of mRNA in all lanes (data not shown).
FIG. 4. Northern blot analysis of total cellular RNAs from both uninfected
and infected hepatocytes and nonparenchymal cells at 24 h after MHV-3 infec-
tion. Lane 1, RNA from MHV-3-infected peritoneal macrophages (positive
control); lanes 2 and 3, RNA from uninfected hepatocytes and nonparenchymal
cells, respectively, lanes 4 and 5, RNA from hepatocytes and nonparenchymal
cells, respectively, at 24 h after MHV-3 infection. Twenty micrograms of total
RNA was added to each lane and hybridized with an fg12 cDNA. A GAPDH
cDNA was used to ensure equal levels of mRNA in all lanes.











The recent molecular characterization of the fgl2 prothrom-
binase now allows for definitive studies to determine the cel-
lular mechanisms involved in the pathogenesis of MHV-3-
induced fulminant hepatic failure. Within 8 h of MHV-3
infection, mRNA transcripts for the murine fgl2 gene were
evident in reticuloendothelial cells of the liver. Within 12 to
24 h MHV-3 infection, expression of the novel fgl2 prothrom-
binase immunoreactivity was detected in liver tissue from sus-
ceptible MHV-3-infected mice. The fgl2 prothrombinase was
seen in endothelial cells lining large veins, in the hepatic sinu-
soids, and in areas of focal necrosis. Shortly thereafter, and
within 24 h, focal deposits of fibrin were found in the liver
sinusoids. By 48 h, the fibrin deposits were extensive and were
accompanied by multifocal confluent hepatocellular necrosis.
Although by Northern blot analysis and in situ hybridization
fgl2 mRNA transcripts were detected in other organs, no trans-
lation product (fgl2 prothrombinase) or disease was seen out-
side the liver despite the presence of high viral titers. Sup-
portive of this observation was the fact that functional
prothrombinase activity was seen only in the liver at 18 hours,
increasing to 72 h and remaining stable at high levels until day
5, the time of death, whereas no such activity was seen in the
lung or spleen at any time point.
MHV can produce a broad spectrum of diseases, including
pneumonitis, encephalitis, enterocolitis, nephritis, and hepati-
tis (30). Although the virus replicates in all tissues, disease is
not seen in tissues in which high viral titers are recovered, and
the pattern of disease is organ specific. Data from our and
other laboratories have suggested that host factors may be
more critical than viral replication in the pathogenesis of MHV
diseases (8, 23, 32). Although in this and previous studies,
replication of MHV-3 was significantly different in each organ
examined, only in the liver is histopathology seen following
MHV-3 infection. Thus, the fact that we saw large differences
in viral replication in tissues in this study following MHV-3
infection was not unexpected and was consistent with other
reports (8). Furthermore, the observation that the spleen and
lungs were anatomically normal yet had high viral titers similar
to those found in the liver supports the concept that viral
replication alone will not explain MHV-3 disease.
Fibrin deposition in the liver is a unique feature of MHV-
3-induced fulminant liver failure, whereas infection of the
brain with MHV-JAM results primarily in demyelination with
no associated fibrin deposition (3, 6, 8). Thus, the detection of
mRNA transcripts in the lung, kidney, and brain following
MHV-3 infection suggests that this gene may be involved in
other MHV diseases. The short time course of MHV-3-in-
duced fulminant hepatic necrosis may preclude development
of disease in these organs.
It is well documented that MHV-3 disease is localized to the
liver and that other organs are relatively spared (22). The fact
that no fgl2 prothrombinase was detected outside the liver was
expected and was consistent with our hypothesis of the impor-
tance of this molecule in the MHV-3-induced liver disease. At
this time, we cannot fully explain why translation of the fgl2
gene does not occur in extrahepatic tissues, but this may reflect
differences in rates of mRNA transcription, mRNA stabilities
in different organs, and/or molecules that interfere with trans-
lation of the gene. These findings are consistent with our pre-
vious study in which mRNA transcripts for fgl2 were evident in
macrophages and liver tissue of resistant A/J mice following
MHV-3 infection (20). However, in this MHV-3-resistant
strain, no fgl2 immunoreactive prothrombinase or liver disease
was seen (20).
Although by the molecular techniques employed it appears
FIG. 5. In situ hybridization detection of fg12 gene expression in the liver. fg12 gene expression was detected by an antisense fg12 probe, to detect sense mRNA.
fg12 transcripts were found in endothelial cells of hepatic veins and sinusoids (thick arrow) and Kupffer cells (thin arrow) 24 h after MHV-3 infection. Hepatic
parenchymal cells were negative. Alkaline phosphatase stain was used. Magnification, 3120.




















that there are fewer steady-state fgl2 mRNA transcripts in the
liver than in other organs, this likely reflects the fact that no
fgl2 mRNA transcripts are expressed either constitutively or
following MHV-3 infection in hepatocytes, which constitute
the major cell type of the liver. Northern analysis of subfrac-
tionated cells from the liver demonstrated high levels of fgl2
mRNA transcripts only in reticuloendothelial cells of the liver.
Our observations are consistent with previous studies show-
ing that the first abnormalities in the liver following MHV-3
infection, as observed by dynamic intravital microscopy, are
disturbances of the liver microcirculation associated with sinu-
soidal microthrombosis (16). At no time was liver necrosis seen
in the absence of fibrin. Thus, these findings firmly establish
the importance of induction of the fgl2 prothrombinase en-
coded by the fgl2 gene in the pathogenesis of hepatocellular
necrosis.
Our previous studies demonstrated that MHV-3 infection of
macrophages resulted in transcription of a number of host
inflammatory cytokines, including TNF-a, IL-1, and superox-
ides (23). Cytokines can play a potent role in the course of
inflammatory injury in vivo, and interference with their action
can alter the courses of certain inflammatory diseases (28, 29).
Treatment of rats with recombinant antibody to TNF has been
shown to protect animals from hypotension, hypothermia, and
mortality of gram-negative sepsis (21), and treatment of rabbits
with an IL-1 receptor antagonist reduced mortality associated
with endotoxin shock (2, 19). We have now shown that both
IL-1 and TNF-a directly induce endothelial cell transcription
of fgl2 (20). The importance of the fgl2 prothrombinase in the
pathogenesis of MHV-3 infection is further supported by the
observation that a neutralizing antibody to this protein pre-
vents fibrin deposition and protects mice from the lethality of
MHV-3 infection (15).
The importance of the immune coagulation system resulting
in fibrin deposition in human fulminant liver failure is contro-
versial (14). Mori et al. have reported that fibrin is a classical
feature of fulminant hepatitis (17, 18), but this has not been
substantiated by others (24, 33). The reason for not finding
fibrin in tissue sections may rest with the methodologies used.
In routine hematoxylin-and-eosin-stained sections, fibrin is not
easily recognized, and its presence is further obscured by he-
patic necrosis. Even the use of special stains for fibrin is not
always conclusive in our experience. However, by using re-
cently available specific antibodies such as those used in this
study, fibrin is clearly evident in the hepatic lesions of MHV-
3-infected livers from susceptible mice. Because of these ob-
servations with MHV-3-infected mice, we have now reexam-
ined liver tissue from patients with fulminant liver failure and
have found fibrin deposits by using methodologies similar to
those described in this report (unpublished data).
In conclusion, fgl2 mRNA transcripts are seen in reticuloen-
dothelial cell-rich organs, including liver, spleen, and lungs,
following MHV-3 infection. However, fgl2 prothrombinase im-
munoreactivity is evident only in the liver. The induction of this
FIG. 7. Immunohistochemical staining of the liver for fibrin. Widespread fibrin deposition (brown) is seen in sinusoids, frequently outlining areas of hepatocellular
necrosis (p). Larger focal areas of fibrin deposition are also seen, with loss of liver cells. Immunoperoxidase stain was used. Magnification, 3400.
FIG. 6. Immunohistochemical staining of the liver after MHV-3 infection by using a rabbit polyclonal antibody against the fg12 prothrombinase. (A) Absence of
staining in a normal control. Magnification, 3100, (B and C) fg12 prothrombinase was detected in the large veins and sinusoids (magnification, 3100) (B) and at 48 h
in sinusoids and necrotic foci (magnification, 3400) (C) by immunofluorescence following MHV-3 infection.










protein in the sinusoids and large portal veins initiates micro-
thrombosis and fibrin deposition, which lead to perturbations
in microvascular hemodynamics and subsequent liver cell ne-
crosis. These studies firmly establish the pivotal role of fgl2 and
its protein product in the pathogenesis of fulminant liver fail-
ure caused by MHV-3.
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